^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Zepsun (donafenib) (Multi-tyrosine kinase inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers
Published date:
10/08/2023
Excerpt:
The combination of SCD1 inhibitor aramchol and deuterated sorafenib derivative donafenib displays promising anti-tumor effects in p53-wild type HCC patient-derived organoids and xenografted tumors.
Secondary therapy:
aramchol meglumine
DOI:
10.1038/s41467-023-41852-z
